Log in

Start Your Membership Now

On July 1, 2025, three new bills in Maryland went into effect to expand access to opioid use disorder treatment by giving local governments greater access to funds from the state’s opioid settlement. Two of the bills modify how the state uses its Opioid Restitution Fund. The third bill establishes a new training program for paramedics to expand the use of buprenorphine. 

The two bills affecting the Opioid Restitution Fund are House Bill 729 (with its companion Senate Bill 594) and House Bill 728 (with its companion Senate Bill 495). According to an analysis of House Bill 729 by . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Addiction Treatment Services

Addiction is a chronic disease, which causes individuals to seek “reward” from substance-use or other activities whether or not they may cause harm. Addiction treatment has been in the spotlight as payers, policymakers, and health systems struggle to address the opioid crisis and increasing substance-related mortality rates. As a result, the addiction treatment market is shifting—there is expanded coverage for residential treatment, a push towards greater integration and care coordination, and new competitors entering the market—creating new challenges and opportunities for organizations working in addiction treatment.

Editor’s Picks

Latest Resources
See All
GLP-1 Medications Linked To 15%–20% Lower Risk Of Substance Use Disorders In Veterans With Type 2 Diabetes
Researchers from the Veterans Affairs St. Louis Health Care System found that veterans with type 2 diabetes who were prescribed glucagon-like peptide-1 receptor agonists (GLP-1s) had a lower risk of developing substance use disorders (SUDs) compared to those prescribed sodium-glucose cotransporter-2 (SGLT-2) inhibitors, according to a study published in The BMJ. The study was conducted to examine whether GLP-1 medications—originally developed to treat type 2 diabetes and increasingly used for weight management—are associated with differences… Read

To sign-up for bi-weekly Mental Health alerts, you must be signed in to your account.

Government Contract Bidding Opportunities

Government Contract Award Announcements